FMC Dialysis - Superior is a medicare approved dialysis facility center in Superior, Wisconsin and it has 8 dialysis stations. It is located in Douglas county at 3500 Tower Avenue, Superior, WI, 54880. You can reach out to the office of FMC Dialysis - Superior at (715) 395-2199. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Dialysis - Superior has the following ownership type - Profit. It was first certified by medicare in September, 2000. The medicare id for this facility is 522538 and it accepts patients under medicare ESRD program.
| Name | FMC Dialysis - Superior |
|---|---|
| Location | 3500 Tower Avenue, Superior, Wisconsin |
| No. of Dialysis Stations | 8 |
| Medicare ID | 522538 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 3500 Tower Avenue, Superior, Wisconsin, 54880 | |
| (715) 395-2199 | |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
| NPI Number | 1306951140 |
| Organization Name | Fmc Dialysis Services Superior |
| Doing Business As | Bio-medical Applications Of Wisconsin, Inc. |
| Address | 3500 Tower Ave Superior, Wisconsin, 54880 |
| Phone Number | (715) 395-2199 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 16 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 19 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 34 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 285 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Dialysis - Superior with elevated calcium levels.
| Patients with hypercalcemia | 35 |
| Hypercalcemia patient months | 297 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 36 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 28 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 35 |
| Patient months included in arterial venous fistula and catheter summaries | 233 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 74 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 26 |
| Hospitalization Rate in facility | 135.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 307.1 |
| Hospitalization Rate: Lower Confidence Limit | 63.5 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Dialysis - Superior were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 11 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 34.1 |
| Readmission Rate: Lower Confidence Limit | 1.6 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Dialysis - Superior get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 3.77 (Worse than Expected) |
| SIR: Upper Confidence Limit | 7.84 |
| SIR: Lower Confidence Limit | 1.53 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Dialysis - Superior's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 25 |
| Transfusion Rate in facility | 29 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 140.8 |
| Transfusion Rate: Lower Confidence Limit | 7.3 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Dialysis - Superior lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 144 |
| Mortality Rate in facility | 19.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 28.3 |
| Mortality Rate: Lower Confidence Limit | 12.8 |
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago
News Archive
Making small, consistent changes to the types of protein- and carbohydrate-rich foods we eat may have a big impact on long-term weight gain, according to a new study led by researchers at the Friedman School of Nutrition Science & Policy at Tufts University.
The goal of "precision oncology" is to be able to tailor treatments to each individual patient based on their cancer's unique molecular fingerprints.
Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.
Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio.
› Verified 6 days ago